CA2174655A1 - New use of prostaglandins - Google Patents

New use of prostaglandins

Info

Publication number
CA2174655A1
CA2174655A1 CA002174655A CA2174655A CA2174655A1 CA 2174655 A1 CA2174655 A1 CA 2174655A1 CA 002174655 A CA002174655 A CA 002174655A CA 2174655 A CA2174655 A CA 2174655A CA 2174655 A1 CA2174655 A1 CA 2174655A1
Authority
CA
Canada
Prior art keywords
prostaglandin
eye
prostaglandins
skin
hair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002174655A
Other languages
English (en)
French (fr)
Inventor
Johan Stjernschantz
Bahram Resul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia AB filed Critical Pharmacia AB
Publication of CA2174655A1 publication Critical patent/CA2174655A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/04—Preparations for care of the skin for chemically tanning the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
    • A61Q5/065—Preparations for temporary colouring the hair, e.g. direct dyes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
CA002174655A 1993-10-20 1994-10-19 New use of prostaglandins Abandoned CA2174655A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9303444-5 1993-10-20
SE9303444A SE9303444D0 (sv) 1993-10-20 1993-10-20 New use of prostaglandins

Publications (1)

Publication Number Publication Date
CA2174655A1 true CA2174655A1 (en) 1995-04-27

Family

ID=20391475

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002174655A Abandoned CA2174655A1 (en) 1993-10-20 1994-10-19 New use of prostaglandins

Country Status (6)

Country Link
EP (1) EP0724425A1 (sv)
JP (1) JPH09504021A (sv)
AU (1) AU8008694A (sv)
CA (1) CA2174655A1 (sv)
SE (1) SE9303444D0 (sv)
WO (1) WO1995011003A1 (sv)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263054B2 (en) 2002-02-04 2012-09-11 Allergan, Inc. Method of enhancing hair growth
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US9750750B2 (en) 2009-11-09 2017-09-05 Allergan, Inc. Compositions and methods for stimulating hair growth

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000100A1 (en) * 1996-07-03 1998-01-08 The Board Of Regents Of The University Of Oklahoma Enhancement of skin pigmentation by prostaglandins
CA2279967C (en) 1997-02-04 2006-08-22 Murray A. Johnstone Method of enhancing hair growth
AU766163B2 (en) 1999-03-05 2003-10-09 Duke University C16 unsaturated fp-selective prostaglandins analogs
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
FR2812190B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
FR2812192B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
KR100437873B1 (ko) 2001-05-08 2004-06-26 연성정밀화학(주) 프로스타글란딘 유도체의 제조방법 및 그의 입체특이적출발물질
EP1594438B1 (fr) 2003-02-12 2013-07-17 L'Oréal Utilisation d'un inhibiteur de 15-hydroxy prostaglandine déshydrogénase pour favoriser la pigmentation de la peau ou des phanères
US7326717B2 (en) 2003-05-06 2008-02-05 L'oreal Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
TWI348386B (en) 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
FR2907682B1 (fr) 2006-10-26 2012-12-07 Vincience Composition cosmetique et/ou pharmaceutique comprenant comme principe actif au moins un peptide et utilisation de ce peptide.
FR2920309B1 (fr) 2007-08-28 2010-05-28 Galderma Res & Dev Utilisation de travoprost pour traiter la chute des cheveux
KR101628415B1 (ko) * 2008-09-04 2016-06-08 산텐 세이야꾸 가부시키가이샤 15,15-디플루오로프로스타글란딘 Ｆ2α 유도체를 유효 성분으로서 함유하는 모발 성장 촉진제
WO2010064203A1 (en) 2008-12-02 2010-06-10 L'oreal Combination of reduced glutathione and amino acids for improving the quality of the hair in women
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
FR2949052B1 (fr) 2009-08-13 2015-03-27 Oreal Procede de traitement cosmetique du cuir chevelu.
FR2951938B1 (fr) 2009-10-30 2012-01-06 Oreal Utilisation d'un extrait de punica granatum pour lutter contre la canitie
FR2978659B1 (fr) 2011-08-05 2014-01-10 Oreal Utilisation de composes cannabinoides pour stimuler la melanogenese
PT2838533T (pt) 2012-04-16 2017-11-22 Univ Texas Composições e métodos de modulação da atividade de 15-pgdh
FR2999932B1 (fr) 2012-12-21 2020-01-31 Société des Produits Nestlé S.A. Utilisation de microorganismes probiotiques comme agent favorisant la synthese de melanine
FR2999931A1 (fr) 2012-12-21 2014-06-27 Oreal Utilisation de microorganismes probiotiques comme agent favorisant la synthese de melanine
US9789116B2 (en) 2013-10-15 2017-10-17 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CA2979203A1 (en) 2015-03-08 2016-09-15 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating fibrosis
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
WO2020106998A1 (en) 2018-11-21 2020-05-28 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
JP2023527279A (ja) 2020-05-20 2023-06-28 ロデオ・セラピューティクス・コーポレイション 短鎖デヒドロゲナーゼ活性を調節する組成物及び方法
CN112933100B (zh) * 2021-04-27 2022-06-24 中国人民解放军空军军医大学 去甲泽拉木醛在白癜风药物上的应用及其软膏

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
EP0302147A1 (en) * 1987-08-03 1989-02-08 The Procter & Gamble Company Topical tanning compositions
FR2623716B1 (fr) * 1987-11-27 1991-04-05 Lvmh Rech Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant de la tyrosine ou un derive de tyrosine et composition cosmetique ou pharmaceutique, notamment dermatologique, a activite pigmentante, l'incorporant
US5352440A (en) * 1988-03-30 1994-10-04 Trustees Of Boston University Methods for increasing melanin content in melanocytes using diacylglycerols and uses thereof
DE4124693A1 (de) * 1991-07-22 1993-01-28 Schering Ag Carbacyclinderivate als mittel zur behandlung von vitiligo

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986715B2 (en) 2002-02-04 2015-03-24 Allergan, Inc. Method of enhancing hair growth
US10159631B2 (en) 2002-02-04 2018-12-25 Allergan, Inc. Method of enhancing hair growth
US8632760B2 (en) 2002-02-04 2014-01-21 Allergan, Inc. Method of enhancing hair growth
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US10188591B2 (en) 2002-02-04 2019-01-29 Allergan, Inc. Method of enhancing hair growth
US8926953B2 (en) 2002-02-04 2015-01-06 Allergan, Inc. Method of enhancing hair growth
US8298518B2 (en) 2002-02-04 2012-10-30 Allergan, Inc. Method of enhancing hair growth
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US8263054B2 (en) 2002-02-04 2012-09-11 Allergan, Inc. Method of enhancing hair growth
US9226931B2 (en) 2002-02-04 2016-01-05 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US9750750B2 (en) 2009-11-09 2017-09-05 Allergan, Inc. Compositions and methods for stimulating hair growth
US9763959B2 (en) 2009-11-09 2017-09-19 Allergan, Inc. Compositions and methods for stimulating hair growth
US9849140B2 (en) 2009-11-09 2017-12-26 Allergan, Inc. Topical compositions comprising bimatoprost and methods for stimulating hair growth therewith
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth

Also Published As

Publication number Publication date
SE9303444D0 (sv) 1993-10-20
JPH09504021A (ja) 1997-04-22
EP0724425A1 (en) 1996-08-07
AU8008694A (en) 1995-05-08
WO1995011003A1 (en) 1995-04-27

Similar Documents

Publication Publication Date Title
CA2174655A1 (en) New use of prostaglandins
JP4397973B2 (ja) 瞼の毛髪の成長を刺激するための局所的組成物
US10188591B2 (en) Method of enhancing hair growth
US7550508B2 (en) Prostaglandin analog compositions and methods to treat epithelial-related conditions
JPH09504543A (ja) 白内障の予防法及び予防手段
HU211593A9 (en) Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US20110112198A1 (en) Compositions for enhancing hair growth
JP2005511650A (ja) 皮膚の色素過剰症の処置法
EP0436010A1 (en) Skin composition to repair the efffects of photoaging
WO2011079154A1 (en) Compositions and methods for treatment of vitiligo
US20190029941A1 (en) Retinoid double conjugate compounds, compositions thereof, and methods for treating of skin conditions
JP4954988B2 (ja) 脂肪族化合物含有美白剤
FR3099057A1 (fr) Inhibiteur du transporteur LAT-1 / SLC7A5 pour son utilisation pour la régulation de la pigmentation cutanée et une composition comprenant ledit inhibiteur
CA2700729A1 (en) Therapeutic agent for vitiligo and method of accelerating pigmentation

Legal Events

Date Code Title Description
FZDE Dead